Vir Biotechnology develops immunology-based therapies targeting infectious diseases through global partnerships and scientific innovation.

Vir Biotechnology develops antibody and RNA-based therapies for infectious diseases, leveraging partnerships and a robust ...

As FDA activity accelerates and big pharma searches for its next generation of blockbuster drugs, select biotech companies ...

The words “sure-fire” and biotechnology stocks rarely go together. This is a sector of the stock market that carries higher-than-average risk. The success of these companies depends on clinical trial ...

ADMA Biologics develops plasma-derived therapies for immune deficiencies and infectious diseases, leveraging a vertically integrated model.

Vir Biotechnology develops immunology-based therapies for infectious diseases, backed by collaborations and a diversified ...

Learning how to trade biotech stocks offers some of the most explosive profit opportunities in the entire market—but also some of its most punishing risks. Biotech stocks can double or triple ...

Immunovant reports clinically meaningful trial results for its lead drug candidate. That’s good news for Roivant Sciences.

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector’s two major indexes — the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) — ...

Onconetix, Inc. (NASDAQ: ONCO) (“Onconetix” or the “Company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for oncology ...

In 2025, biotechnology stocks had their best year since the COVID-19 pandemic, with the market sector's two major indexes - the SDPR S&P Biotech ETX (NYSE: XBI) and iShares Biotech ETF (NYSE: IBB) - ...

Top 10 mid-cap stocks by YTD performance amid market volatility—see 600%+ gainers across semis, biotech & more, plus mid-cap ...